A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration
Completed · Phase 1 · NCT06278766
Conditions: Healthy Volunteer
At a glance
- Research payments reported, 2025
- $174,488
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 8
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-552 (drug)
- Dates
- Started 2024-02-21; completion 2024-04-19
- Results posted
- Not yet
The purpose of this study is to evaluate mass balance, pharmacokinetics and safety of \[14C\] ABBV-552 in healthy, male volunteers following administration of a single oral dose.
From ClinicalTrials.gov, last updated 2024-04-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $174,488 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Fortrea Clinical Research Unit Inc $174,488
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.